Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission - Institut Pasteur Access content directly
Journal Articles Emerging Infectious Diseases Year : 2018

Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission

Abstract

We conducted a multicenter, retrospective cohort study of hospitalized patients with serologically proven nephropathia epidemica (NE) living in Ardennes Department, France, during 2000-2014 to develop a bioclinical test predictive of severe disease. Among 205 patients, 45 (22.0%) had severe NE. We found the following factors predictive of severe NE: nephrotoxic drug exposure (p = 0.005, point value 10); visual disorders (p = 0.02, point value 8); microscopic or macroscopic hematuria (p = 0.04, point value 7); leukocyte count >10 × 109 cells/L (p = 0.01, point value 9); and thrombocytopenia <90 × 109/L (p = 0.003, point value 11). When point values for each factor were summed, we found a score of <10 identified low-risk patients (3.3% had severe disease), and a score >20 identified high-risk patients (45.3% had severe disease). If validated in future studies, this test could be used to stratify patients by severity in research studies and in clinical practice.
Fichier principal
Vignette du fichier
17-2160.pdf (1.39 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

pasteur-01834306 , version 1 (10-07-2018)

Licence

Attribution

Identifiers

Cite

Maxime Hentzien, Stéphanie Mestrallet, Pascale Halin, Laure-Anne Pannet, Delphine Lebrun, et al.. Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission. Emerging Infectious Diseases, 2018, 24 (6), pp.1045 - 1054. ⟨10.3201/eid2406.172160⟩. ⟨pasteur-01834306⟩

Collections

PASTEUR
166 View
162 Download

Altmetric

Share

Gmail Facebook X LinkedIn More